These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 27856426

  • 1. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
    Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, Richards WG, Barbie DA, Bass AJ, Rodig SJ, Hodi FS, Wucherpfennig KW, Jänne PA, Sholl LM, Hammerman PS, Wong KK, Bueno R.
    Cancer Immunol Res; 2016 Dec; 4(12):1038-1048. PubMed ID: 27856426
    [Abstract] [Full Text] [Related]

  • 2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 3. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
    Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, Mitchell P, Watkins DN, Boutros PC, John T.
    J Thorac Oncol; 2017 May 01; 12(5):850-859. PubMed ID: 28257959
    [Abstract] [Full Text] [Related]

  • 4. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun 01; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 5. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.
    Mod Pathol; 2020 Feb 01; 33(2):303-311. PubMed ID: 31537897
    [Abstract] [Full Text] [Related]

  • 6. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep 01; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

  • 7. Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
    Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R.
    J Thorac Oncol; 2016 Nov 01; 11(11):1993-2005. PubMed ID: 27544053
    [Abstract] [Full Text] [Related]

  • 8. Characterization of Pleural Mesothelioma by Hierarchical Clustering Analyses Using Immune Cells within Tumor Microenvironment.
    Inaguma S, Wang C, Ito S, Ueki A, Lasota J, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Takiguchi S, Schrump DS, Miettinen M, Takahashi S.
    Pathobiology; 2024 Nov 01; 91(5):313-325. PubMed ID: 38527431
    [Abstract] [Full Text] [Related]

  • 9. CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
    Inaguma S, Ueki A, Lasota J, Komura M, Sheema AN, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Schrump DS, Hassan R, Miettinen M, Takahashi S.
    J Pathol Clin Res; 2023 May 01; 9(3):195-207. PubMed ID: 36754859
    [Abstract] [Full Text] [Related]

  • 10. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M.
    Hum Pathol; 2018 Jan 01; 71():1-7. PubMed ID: 28811252
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M, Rouquette I, Adam J, Cortot A, Cazes A, Gibault L, Damotte D, Lantuejoul S.
    Ann Pathol; 2017 Feb 01; 37(1):61-78. PubMed ID: 28162296
    [Abstract] [Full Text] [Related]

  • 12. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.
    Prado-Garcia H, Romero-Garcia S, Puerto-Aquino A, Rumbo-Nava U.
    Cancer Immunol Immunother; 2017 Jun 01; 66(6):765-776. PubMed ID: 28289860
    [Abstract] [Full Text] [Related]

  • 13. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV.
    J Thorac Oncol; 2018 Jan 01; 13(1):124-133. PubMed ID: 29079455
    [Abstract] [Full Text] [Related]

  • 14. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
    de Perrot M, Wu L, Cabanero M, Perentes JY, McKee TD, Donahoe L, Bradbury P, Kohno M, Chan ML, Murakami J, Keshavjee S, Tsao MS, Cho BCJ.
    J Thorac Cardiovasc Surg; 2020 May 01; 159(5):2082-2091.e1. PubMed ID: 31866087
    [Abstract] [Full Text] [Related]

  • 15. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb 01; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

  • 16. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
    Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA.
    J Immunother Cancer; 2023 Oct 01; 11(10):. PubMed ID: 37880184
    [Abstract] [Full Text] [Related]

  • 17. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
    Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R.
    Int J Mol Sci; 2018 Mar 30; 19(4):. PubMed ID: 29601534
    [Abstract] [Full Text] [Related]

  • 18. Flowcytometric immunophenotyping of peripheral-blood leukocytes in relation to immunopathology and cellular proliferation of pleural mesothelioma.
    ElGendy AM, Abbas Helmy WH, Ezz-ElArab A.
    Egypt J Immunol; 2006 Mar 30; 13(1):87-98. PubMed ID: 17974153
    [Abstract] [Full Text] [Related]

  • 19. Expression of V-set immunoregulatory receptor in malignant mesothelioma.
    Chung YS, Kim M, Cha YJ, Kim KA, Shim HS.
    Mod Pathol; 2020 Feb 30; 33(2):263-270. PubMed ID: 31363159
    [Abstract] [Full Text] [Related]

  • 20. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E, Kajino K, Abe M, Ohtsuji N, Saeki H, Hlaing MT, Hino O.
    Pathol Int; 2020 Dec 30; 70(12):999-1008. PubMed ID: 33027549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.